CTLA4 and cancer: Consequently, multiple clinical trials of NKTR-214 in combination with anti-PD-1, anti-CTLA-4, or other agents in multiple cancer histologies are currently underway (e.g., NCT02983045, NCT03138889, NCT03435640, NCT03635983).